Observations on the Pymaceuticals animal study

The drug Capomulin had a positive impact on the tumor volume reduction over the 45 days of trial period. The mean tumor volume decreased from 45.00mm3 to 36.23mm3.

The remaining 2 drugs, i.e., Infubinol, and Ketapril, performed about the same as the Placebo. The mean tumor volume increased from 45.00mm3 to >=65.00mm3

While the mean metastatic spread increased, the mean spread for the Capomulin increased at a lower rate. In addition, Capomulin had a higher survival rate at 45 days (21 out of 25 mice survived the trial period).

Overall, Capomulin shows positive impact on Tumor based on the trial data.

